Purple Biotech (PPBT) Receivables - Other (2014 - 2024)
Purple Biotech's (PPBT) quarterly Receivables - Other came in at $1000.0 in Q4 2024, little changed year-over-year from $1000.0 in Q1 2024, and little changed quarter-over-quarter from $1000.0 in Q4 2023.
Powered by 
Analysis
Purple Biotech (PPBT) Receivables - Other (2014 - 2024) Analysis & Trends
Purple Biotech (PPBT) has reported Receivables - Other for 7 consecutive years, with $1000.0 the latest figure, recorded in Q4 2024.
- On a quarterly basis, Receivables - Other changed 0.0% year-over-year to $1000.0 in Q4 2024; TTM through Dec 2024 was $1000.0, a 0.0% change from a year earlier, with the FY2024 full-year figure at $1000.0, changed 0.0% from the prior year.
- Receivables - Other was $1000.0 for Q4 2024 at Purple Biotech, roughly flat from $1000.0 in the prior quarter.
- Over five years, Receivables - Other peaked at $1000.0 in Q4 2023 and troughed at $1000.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.46 Bn | 192.47 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.92 Bn | 176.75 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.37 Bn | 123.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.86 Bn | 73.87 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.29 Bn | 55.10 Bn | 1.37 Bn |
| 6 | Moderna | 53.76 Bn | 48.62 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.16 Bn | 29.85 Bn | 992.69 Mn |
| 8 | Biogen | 31.90 Bn | 30.62 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.13 Bn | 29.13 Bn | 1.16 Mn |
| 10 | Purple Biotech | 291,843.46 | 291,843.46 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 1,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Dec 31, 2018 | -1.31 Mn |
| Dec 31, 2017 | -273,000.00 |
| Jun 30, 2017 | 762,000.00 |
| Dec 31, 2016 | 241,000.00 |
| Jun 30, 2016 | 644,000.00 |
| Dec 31, 2015 | 197,000.00 |
| Sep 30, 2015 | 553,000.00 |
| Dec 31, 2014 | -375,000.00 |
| Sep 30, 2014 | 445,000.00 |